CD30-positive peripheral T-cell lymphomas share molecular and phenotypic features

Haematologica

Volumn 98, Issue 8, 2013, Pages 1250-1258

  Bisig, Bettina ^a,b,c   de Reyniès, Aurélien ^d   Bonnet, Christophe ^b   Sujobert, Pierre ^e   Rickman, David S ^f   Marafioti, Teresa ^g   Delsol, Georges ^h   Lamant, Laurence ^h   Gaulard, Philippe ^e,i,j   de Leval, Laurence ^a,b,c  

^a UNIVERSITY INSTITUTE OF PATHOLOGY   (Switzerland)

^b UNIVERSITY OF LIÈGE   (Belgium)

^c UNIVERSITY OF LIÈGE   (Belgium)

^d Ligue Nationale Contre le Cancer   (France)

^e HENRI MONDOR HOSPITAL   (France)

^f WEILL CORNELL MEDICAL COLLEGE   (United States)

^g UNIVERSITY COLLEGE HOSPITAL   (United Kingdom)

^h CHU PURPAN   (France)

ⁱ INSERM U955   (France)

^j UNIVERSITÉ PARIS EST CRÉTEIL   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; CD3 ANTIGEN; CD30 ANTIGEN; CD52 ANTIGEN; CD69 ANTIGEN; CYCLIN D3; EPITHELIAL MEMBRANE ANTIGEN; INDUCIBLE T CELL COSTIMULATOR LIGAND; PROTEIN KINASE FYN; PROTEIN KINASE LCK; PROTEIN KINASE SYK; PROTEIN KINASE ZAP 70; STAT3 PROTEIN; T LYMPHOCYTE RECEPTOR; TRANSCRIPTION FACTOR GATA 1; TRANSCRIPTION FACTOR NFAT;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CLUSTER ANALYSIS; DOWN REGULATION; FEMALE; GENE EXPRESSION PROFILING; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PHYLOGENETIC TREE; T CELL LYMPHOMA; UPREGULATION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD30; CHILD; CHILD, PRESCHOOL; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION PROFILING; HUMANS; LYMPHOMA, T-CELL, PERIPHERAL; MALE; MIDDLE AGED; PHENOTYPE; YOUNG ADULT;

EID: 84881010867     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2012.081935     Document Type: Article

References (38)

1. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon: IARC; 2008.
2. Stein H, Mason DY, Gerdes J, O'Connor N, Wainscoat J, Pallesen G, et al. The expression of the Hodgkin's disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells. Blood. 1985;66(4):848-58.
3. Stein H, Foss HD, Durkop H, Marafioti T, Delsol G, Pulford K, et al. CD30(+) anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features. Blood. 2000;96(12):3681-95.
4. Jaffe ES, Harris NL, Stein H, Vardiman JW. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 3rd ed. Lyon: IARC; 2001.
5. Savage KJ, Harris NL, Vose JM, Ullrich F, Jaffe ES, Connors JM, et al. ALK-anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project. Blood. 2008;111(12): 5496-504.
6. Thompson MA, Stumph J, Henrickson SE, Rosenwald A, Wang Q, Olson S, et al. Differential gene expression in anaplastic lymphoma kinase-positive and anaplastic lymphoma kinase-negative anaplastic large cell lymphomas. Hum Pathol. 2005;36(5): 494-504.
7. Lamant L, de Reynies A, Duplantier MM, Rickman DS, Sabourdy F, Giuriato S, et al. Gene-expression profiling of systemic anaplastic large-cell lymphoma reveals differences based on ALK status and two distinct morphologic ALK+ subtypes. Blood. 2007;109(5):2156-64.
8. Jaffe ES. The 2008 WHO classification of lymphomas: implications for clinical practice and translational research. Hematology Am Soc Hematol Educ Program. 2009:523-31.
9. Weisenburger DD, Savage KJ, Harris NL, Gascoyne RD, Jaffe ES, MacLennan KA, et al. Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the International Peripheral T-cell Lymphoma Project. Blood. 2011;117(12): 3402-8.
10. Went P, Agostinelli C, Gallamini A, Piccaluga PP, Ascani S, Sabattini E, et al. Marker expression in peripheral T-cell lymphoma: a proposed clinical-pathologic prognostic score. J Clin Oncol. 2006;24(16):2472-9.
11. Barry TS, Jaffe ES, Sorbara L, Raffeld M, Pittaluga S. Peripheral T-cell lymphomas expressing CD30 and CD15. Am J Surg Pathol. 2003;27(12):1513-22.
12. Piccaluga PP, Agostinelli C, Califano A, Rossi M, Basso K, Zupo S, et al. Gene expression analysis of peripheral T cell lymphoma, unspecified, reveals distinct profiles and new potential therapeutic targets. J Clin Invest. 2007;117(3):823-34.
13. Piva R, Agnelli L, Pellegrino E, Todoerti K, Grosso V, Tamagno I, et al. Gene expression profiling uncovers molecular classifiers for the recognition of anaplastic large-cell lymphoma within peripheral T-cell neoplasms. J Clin Oncol. 2010;28(9):1583-90.
14. Agnelli L, Mereu E, Pellegrino E, Limongi T, Kwee I, Bergaggio E, et al. Identification of a 3-gene model as a powerful diagnostic tool for the recognition of ALK-negative anaplastic large-cell lymphoma. Blood. 2012;120 (6):1274-81.
15. Martinez-Delgado B, Cuadros M, Honrado E, Ruiz de la Parte A, Roncador G, Alves J, et al. Differential expression of NF-kappaB pathway genes among peripheral T-cell lymphomas. Leukemia. 2005;19(12):2254-63.
16. Ballester B, Ramuz O, Gisselbrecht C, Doucet G, Loi L, Loriod B, et al. Gene expression profiling identifies molecular subgroups among nodal peripheral T-cell lymphomas. Oncogene. 2006;25(10):1560-70.
17. Cuadros M, Dave SS, Jaffe ES, Honrado E, Milne R, Alves J, et al. Identification of a proliferation signature related to survival in nodal peripheral T-cell lymphomas. J Clin Oncol. 2007;25(22):3321-9.
18. Iqbal J, Weisenburger DD, Greiner TC, Vose JM, McKeithan T, Kucuk C, et al. Molecular signatures to improve diagnosis in peripheral T-cell lymphoma and prognostication in angioimmunoblastic T-cell lymphoma. Blood. 2010;115(5):1026-36.
19. de Leval L, Rickman DS, Thielen C, Reynies A, Huang YL, Delsol G, et al. The gene expression profile of nodal peripheral T-cell lymphoma demonstrates a molecular link between angioimmunoblastic T-cell lymphoma (AITL) and follicular helper T (TFH) cells. Blood. 2007;109(11):4952-63.
20. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledgebased approach for interpreting genomewide expression profiles. Proc Natl Acad Sci USA. 2005;102(43):15545-50.
21. Bonzheim I, Geissinger E, Roth S, Zettl A, Marx A, Rosenwald A, et al. Anaplastic large cell lymphomas lack the expression of T-cell receptor molecules or molecules of proximal T-cell receptor signaling. Blood. 2004;104 (10):3358-60.
22. Geissinger E, Sadler P, Roth S, Grieb T, Puppe B, Muller N, et al. Disturbed expression of the T-cell receptor/CD3 complex and associated signaling molecules in CD30+ Tcell lymphoproliferations. Haematologica. 2010;95(10):1697-704.
23. Feldman AL, Sun DX, Law ME, Novak AJ, Attygalle AD, Thorland EC, et al. Overexpression of Syk tyrosine kinase in peripheral T-cell lymphomas. Leukemia. 2008;22(6):1139-43.
24. Rassidakis GZ, Thomaides A, Atwell C, Ford R, Jones D, Claret FX, et al. JunB expression is a common feature of CD30+ lymphomas and lymphomatoid papulosis. Mod Pathol. 2005;18(10):1365-70.
25. Walker RA. Quantification of immunohistochemistry--issues concerning methods, utility and semiquantitative assessment I. Histopathology. 2006;49(4):406-10.
26. Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25(5):579-86.
27. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-81.
28. Cox DR. Regression models and life tables. J R Stat Soc. 1972;34:187-220.
29. Eisen MB, Spellman PT, Brown PO, Botstein D. Cluster analysis and display of genomewide expression patterns. Proc Natl Acad Sci USA. 1998;95(25):14863-8.
30. Natkunam Y, Tedoldi S, Paterson JC, Zhao S, Rodriguez-Justo M, Beck AH, et al. Characterization of c-Maf transcription factor in normal and neoplastic hematolymphoid tissue and its relevance in plasma cell neoplasia. Am J Clin Pathol. 2009;132(3): 361-71.
31. Lupher ML, Jr., Rao N, Lill NL, Andoniou CE, Miyake S, Clark EA, et al. Cbl-mediated negative regulation of the Syk tyrosine kinase. A critical role for Cbl phosphotyrosine-binding domain binding to Syk phosphotyrosine 323. J Biol Chem. 1998;273(52): 35273-81.
32. Chiarle R, Voena C, Ambrogio C, Piva R, Inghirami G. The anaplastic lymphoma kinase in the pathogenesis of cancer. Nat Rev Cancer. 2008;8(1):11-23.
33. de Leval L, Gaulard P. CD30+ lymphoproliferative disorders. Haematologica. 2010;95 (10):1627-30.
34. Piva R, Pellegrino E, Mattioli M, Agnelli L, Lombardi L, Boccalatte F, et al. Functional validation of the anaplastic lymphoma kinase signature identifies CEBPB and BCL2A1 as critical target genes. J Clin Invest. 2006;116(12):3171-82.
35. Sibon D, Fournier M, Briere J, Lamant L, Haioun C, Coiffier B, et al. Long-term outcome of adults with systemic anaplastic large-cell lymphoma treated within the Groupe d'Etude des Lymphomes de l'Adulte Trials. J Clin Oncol. 2012; 30(32):3939-46.
36. ten Berge RL, de Bruin PC, Oudejans JJ, Ossenkoppele GJ, van der Valk P, Meijer CJ. ALK-negative anaplastic large-cell lymphoma demonstrates similar poor prognosis to peripheral T-cell lymphoma, unspecified. Histopathology. 2003;43(5):462-9.
37. Macon WR, Maurer MJ, Said J, Rodig SJ, Gascoyne RD, Dorfman DM, et al. Clinicopathologic features of anaplastic large cell lymphoma (ALCL), ALK-and CD30+ peripheral T-Cell lymphoma, not otherwise specified (PTCL, nos): a study from the North American T-Cell Lymphoma Consortium. Mod Pathol. 2013;26(2s):343A.
38. Foyil KV, Bartlett NL. Brentuximab vedotin for the treatment of CD30+ lymphomas. Immunotherapy. 2011;3(4):475-85.